This post was originally published on this site

DexCom, Inc. (NASDAQ:DXCM) price on Friday, Jun 04, rose 1.64% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $382.91.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

A look at the stock’s price movement, the close in the last trading session was $376.74, moving within a range at $378.35 and $387.95. The beta value (5-Year monthly) was 0.75 while the PE ratio in trailing twelve months stood at 73.85. Turning to its 52-week performance, $456.23 and $305.63 were the 52-week high and 52-week low respectively. Overall, DXCM moved 4.64% over the past month.

DexCom, Inc.’s market cap currently stands at around $36.28 Billion, with investors looking forward to this quarter’s earnings report slated for Jul 26, 2021- Jul 30, 2021. The company has a Forward Dividend ratio of 0, with its dividend yield at 0%. As such, investors might be keen on a downside in the stock’s price ahead of the scheduled earnings report. Analysts project the company’s earnings per share (EPS) to be $0.45, which has seen fiscal year 2021 EPS growth forecast to decrease to $2.26 and about $3.32 for fiscal year 2022. Per the data, EPS growth is expected to be -0.27% for 2021 and 0.47% for the next financial year.

Turning to the stock’s technical picture we see that short term indicators suggest on average that DXCM is a 50% Sell. On the other hand, the stock is on average a Hold as suggested by medium term indicators while long term indicators are putting the stock in 100% Buy category.

22 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 3 analyst(s) rate the stock as a Hold, 15 recommend DXCM as a Buy and 3 give it an Outperform rating. Meanwhile, 1 analyst(s) rate the stock as Underperform and none say it is a Sell. As such, the average rating for the stock is Overweight which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.

The technical evaluation for the stock shows the PEG ratio is 3.13, with DXCM’s current price about 9.72% and 3.51% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 61.47, while 7-day volatility ratio is 3.13% and 3.68% in the 30-day chart. Further, DexCom, Inc. (DXCM) has a beta value of 0.75, and an average true range (ATR) of 13.42. Analysts have given the company’s stock an average 52-week price target of $475.05, forecast between a low of $380 and high of $540. Looking at the price targets, the low is -0.76% off current price level while to achieve the yearly target high, price needs to move +41.03%. Nonetheless, investors will most likely welcome a +25.88% jump to $482 which is the analysts’ median price.

In the market, a comparison of DexCom, Inc. (DXCM) and its peers suggest the former has performed considerably weaker. Data shows DXCM’s intraday price has changed +1.64% in last session and +11.04% over the past year. Comparatively, Thermo Fisher Scientific Inc (TMO) has moved +0.77% on the day and only +28.9% in the past 12 months. Looking at another peer, we see that Intuitive Surg Inc (ISRG) price has surged 1.81% on the day. However, the stock is 47.35% off its price a year ago. Moreover, Edwards Lifesciences Corp (EW) is also up 1.64% in trading on the day while keeping an uptrend of 11.04% over the past year. If we look at the PE ratio, we find that DexCom, Inc.’s ratio stands at 73.85 compared to Thermo Fisher Scientific Inc’s 22.56 and Intuitive Surg Inc’s 85.73. Elsewhere, the overall performance for the S&P 500 and Dow Jones Industrial shows that the indexes are up 0.88% and 0.52% respectively in the last trading.

If we refocus on DexCom, Inc. (NASDAQ:DXCM), historical trading data shows that trading volumes averaged 883.85 Million over the past 10 days and 811.12 Million over the past 3 months. The company’s latest data on shares outstanding shows there are 96.71 Million shares.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

As per Thomson Reuters, 0.54% of DexCom, Inc.’s shares are in the hands of company insiders while institutional holders own 95.92% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 3.64 Million on April 14, 2021, giving us a short ratio of 5.1. The data shows that as of April 14, 2021 short interest in DexCom, Inc. (DXCM) stood at 3.76% of shares outstanding, with shares short dropping from 3.68 Million registered in March. Current price change has pushed the stock +3.57% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the DXCM stock continues to rise going into the next quarter.